Featured Publications
Patient-level and external factors in the use of drug-coated balloons and drug-eluting stents in femoropopliteal endovascular interventions
Castro-Dominguez Y, Smolderen KG, Pichert M, Alabi O, Romain G, Huang J, Lee M, Ahmed Z, Peri-Okonny PA, Arham A, Brice A, Chaar CO, Stacy MR, Mena-Hurtado C. Patient-level and external factors in the use of drug-coated balloons and drug-eluting stents in femoropopliteal endovascular interventions. Journal Of Vascular Surgery 2022, 76: 1675-1680. PMID: 35868423, DOI: 10.1016/j.jvs.2022.06.093.Peer-Reviewed Original ResearchMeSH KeywordsAgedAngioplasty, BalloonCoated Materials, BiocompatibleDrug-Eluting StentsFemaleFemoral ArteryHumansMedicarePeripheral Arterial DiseasePopliteal ArteryTreatment OutcomeUnited StatesVascular PatencyConceptsDrug-coated balloonsDrug-eluting stentsBare metal stentsDES useFemoropopliteal endovascular interventionEndovascular interventionMedian odds ratioFemoropopliteal diseaseLesion characteristicsPrimary treatmentChronic kidney disease stage 4Adjusted median odds ratioVascular Quality Initiative registryAppropriate use guidelinesPrior anticoagulant usePatient-level factorsPoor functional statusTrans-Atlantic InterPlain balloon angioplastyPatient-level characteristicsFavorable patency ratesHierarchical logistic regression modelsLogistic regression modelsMeta-analysis publicationsRutherford classificationUse of drug-coated balloons and stents in patients with femoropopliteal artery disease and severe chronic kidney disease
Castro-Dominguez Y, Smolderen K, Romain G, Turner J, Mena-Hurtado C. Use of drug-coated balloons and stents in patients with femoropopliteal artery disease and severe chronic kidney disease. Vascular Medicine 2023, 28: 150-152. PMID: 36710497, DOI: 10.1177/1358863x221148521.Peer-Reviewed Original ResearchMeSH KeywordsAngioplasty, BalloonCoated Materials, BiocompatibleFemoral ArteryHumansPeripheral Arterial DiseasePopliteal ArteryStentsTreatment OutcomeVascular Patency
2023
Drug‐Coated Balloon and Drug‐Eluting Stent Safety in Patients With Femoropopliteal and Severe Chronic Kidney Disease
Hanna J, Smolderen K, Castro‐Dominguez Y, Romain G, Lee M, Turner J, Mena‐Hurtado C. Drug‐Coated Balloon and Drug‐Eluting Stent Safety in Patients With Femoropopliteal and Severe Chronic Kidney Disease. Journal Of The American Heart Association 2023, 12: e028622. PMID: 36974774, PMCID: PMC10122876, DOI: 10.1161/jaha.122.028622.Peer-Reviewed Original ResearchMeSH KeywordsAgedAngioplasty, BalloonCoated Materials, BiocompatibleDrug-Eluting StentsFemoral ArteryHumansMedicarePeripheral Arterial DiseasePopliteal ArteryTreatment OutcomeUnited StatesConceptsEarly-stage chronic kidney diseaseChronic kidney diseaseBare metal stentsDrug-eluting stentsDrug-coated balloonsMortality riskAmputation riskKidney diseaseSevere chronic kidney diseaseMajor amputation riskPlain balloon angioplastyDrug-Coated BalloonAmputation outcomesCKD statusAmputation rateCause mortalityBackground PatientsAdjusted analysisBalloon angioplastyFemoropopliteal interventionsDES useBMS useRegistry dataDisease trialsPatients
2021
Trends in drug-coated device use for peripheral artery disease: Insights from the Vascular Quality Initiative (VQI)
Pichert MD, Smolderen KG, Castro-Dominguez Y, Jelani QU, Nagpal S, Provance JB, Huang J, Malik AO, Secemsky EA, Derbas LA, Mena-Hurtado CI. Trends in drug-coated device use for peripheral artery disease: Insights from the Vascular Quality Initiative (VQI). Vascular Medicine 2021, 27: 73-74. PMID: 34610776, DOI: 10.1177/1358863x211043567.Peer-Reviewed Original ResearchMeSH KeywordsAngioplasty, BalloonCoated Materials, BiocompatibleFemoral ArteryHumansPeripheral Arterial DiseasePopliteal ArteryTreatment Outcome
2020
Outcomes of treatment with paclitaxel-coated devices for peripheral arterial disease
Kim TI, Kiwan G, Mohamedali A, Zhang Y, Mena-Hurtado C, Mojibian H, Guzman RJ, Ochoa Chaar CI. Outcomes of treatment with paclitaxel-coated devices for peripheral arterial disease. Journal Of Vascular Surgery 2020, 73: 911-917. PMID: 33038480, DOI: 10.1016/j.jvs.2020.08.146.Peer-Reviewed Original ResearchMeSH KeywordsAgedAged, 80 and overAmputation, SurgicalCardiovascular AgentsCoated Materials, BiocompatibleDrug-Eluting StentsEndovascular ProceduresFemaleHumansLimb SalvageMaleMiddle AgedPaclitaxelPeripheral Arterial DiseaseProsthesis DesignRetreatmentRetrospective StudiesRisk AssessmentRisk FactorsTime FactorsTreatment OutcomeVascular PatencyConceptsPaclitaxel-coated devicesPeripheral artery diseaseCause of mortalityPCD useRisk of mortalityCumulative doseFemoropopliteal peripheral artery diseaseKaplan-Meier survival curvesLong-term mortalityPeripheral arterial diseaseCox regression analysisDrug-coated balloonsOutcome of treatmentDrug-eluting stentsMajor amputationPrimary patencyReintervention rateArtery diseaseArterial diseaseRandomized trialsOpen surgeryPresent studySingle institutionEndovascular interventionPatients
2019
Drug‐coated balloon versus plain old balloon angioplasty in femoropopliteal disease: An updated meta‐analysis of randomized controlled trials
Anantha‐Narayanan M, Shah SM, Jelani Q, Garcia S, Ionescu C, Regan C, Mena‐Hurtado C. Drug‐coated balloon versus plain old balloon angioplasty in femoropopliteal disease: An updated meta‐analysis of randomized controlled trials. Catheterization And Cardiovascular Interventions 2019, 94: 139-148. PMID: 30838719, DOI: 10.1002/ccd.28176.Peer-Reviewed Original ResearchMeSH KeywordsAgedAmputation, SurgicalAngioplasty, BalloonCardiovascular AgentsCoated Materials, BiocompatibleEquipment DesignFemaleFemoral ArteryHumansLimb SalvageMalePeripheral Arterial DiseasePopliteal ArteryRandomized Controlled Trials as TopicRisk FactorsTreatment OutcomeVascular Access DevicesVascular PatencyConceptsTarget vessel revascularizationPeripheral arterial diseaseFemoropopliteal diseaseBalloon angioplastyRate of TVRDrug-coated balloon angioplastyPlain old balloon angioplastyAvailable RCT dataDevice-related mortalityImproved vessel patencyPrimary safety endpointMainstay of therapyCochrane's Q statisticLate lumen lossDrug-coated balloonsRandom-effects modelQ statisticMajor amputationSafety endpointVessel revascularizationDCB groupPopliteal arteryArterial diseaseUse of DCBLumen loss
2017
Stellarex Drug-Coated Balloon for Treatment of Femoropopliteal Disease
Krishnan P, Faries P, Niazi K, Jain A, Sachar R, Bachinsky WB, Cardenas J, Werner M, Brodmann M, Mustapha JA, Mena-Hurtado C, Jaff MR, Holden AH, Lyden SP, Mewissen M, Katzen B, Nanjundappa A, Khuddus M, Ricci J, Fry D, Shishehbor M, Bosarge C, Kovach R, Goodwin M, Raja M, Mayeda G, Sandhu J, Rosales O, Crowder W, Paolini D, Henretta J, Desai P, Farhat N, Kang E, Ansel G, Ghani M, Miller W, Pollock C, Korngold E, Angle J, Schultz G, Gensler T, Lopez L, Park J, Al-Khoury G, Joels C, Metzger C. Stellarex Drug-Coated Balloon for Treatment of Femoropopliteal Disease. Circulation 2017, 136: 1102-1113. PMID: 28729250, PMCID: PMC5598919, DOI: 10.1161/circulationaha.117.028893.Peer-Reviewed Original ResearchMeSH KeywordsAgedAngioplasty, BalloonCardiovascular AgentsCoated Materials, BiocompatibleFemaleFemoral ArteryHalf-LifeHumansKaplan-Meier EstimateMaleMiddle AgedPaclitaxelPeripheral Arterial DiseaseProspective StudiesSeverity of Illness IndexSingle-Blind MethodTime FactorsTreatment OutcomeVascular PatencyConceptsDrug-coated balloonsPrimary safety end pointSafety end pointTarget lesion revascularizationLesion revascularizationPrimary patencyEnd pointFemoropopliteal diseaseClinical outcomesPivotal studiesDifferent drug-coated balloonsPrimary effectiveness end pointStellarex drug-coated balloonTarget limb major amputationEffectiveness end pointAnkle-brachial indexProcedure-related deathsFemoropopliteal artery diseasePrimary patency rateDrug-Coated BalloonKaplan-Meier estimatesPaclitaxel plasma concentrationsQuality of lifeDCB cohortMajor amputation